Biotech | January 20, 2026
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
India in the Changing Landscape of Life-Sciences Research & Development
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
The non-dilutive financing includes three tranches
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Subscribe To Our Newsletter & Stay Updated
